FPX - ETF AI Analysis
Top Page
First Trust US Equity Opportunities ETF (FPX)
FPX, the First Trust US Equity Opportunities ETF, appears to offer a solid but not top-tier profile, driven largely by strong contributors like Corpay, Eli Lilly, and Goldman Sachs, which bring robust financial performance, positive earnings outlooks, and growth initiatives to the portfolio. However, holdings such as SanDisk and Lumentum introduce concerns around valuation, profitability, and operational challenges, and several positions face high leverage or cash flow risks. The main risk factor is the fund’s exposure to multiple companies with valuation and financial-performance issues, which could increase volatility despite the generally positive momentum in many of its top holdings.
FPX vs. SPDR S&P 500 ETF (SPY)
- AUM
- 1.35B
- Region
- North America
- Expense Ratio
- 0.57%
- Beta
- 1.47
- Issuer
- First Trust
- Inception Date
- Apr 12, 2006
- Dividend Yield
- 0.49%
- Asset Class
- Equity
- Index Tracked
- IPOX-100 U.S. Index
FPX Summary
FPX, the First Trust US Equity Opportunities ETF, follows the IPOX-100 U.S. Index, which focuses on newly public U.S. companies, including recent IPOs and spinoffs. It owns a mix of sectors like health care, technology, and industrials, with well-known names such as SpaceX and Eli Lilly. Investors might consider FPX if they want growth potential from newer, fast-moving companies while still getting diversification across many industries. A key risk is that newer stocks can be more volatile, so the ETF’s value can rise and fall sharply with market swings and the fortunes of these young companies.
How much will it cost me?
This ETF has an expense ratio of 0.57%, which means you’ll pay about $5.70 per year for every $1,000 you invest. That’s higher than the average low-cost index ETF because FPX follows a more specialized, rules-based strategy focused on newly public companies rather than a plain-vanilla broad market index.
What would affect this ETF?
FPX could benefit if the U.S. economy stays strong, new IPO activity remains healthy, and innovation in areas like health care and technology boosts companies such as Eli Lilly, SpaceX, and other top holdings. On the downside, higher interest rates, tighter regulations on tech or health care, or a slowdown in IPO markets and U.S. growth could hurt these newer, more volatile companies and weigh on the ETF’s performance.
FPX Top 10 Holdings
FPX is leaning heavily on a handful of newly public U.S. names, with GE Vernova and Eli Lilly acting as the core engines of the portfolio—GEV has been rising this year, while Lilly’s gains have been steadier but still supportive. The real fireworks come from SanDisk and Seagate, where strong recent momentum in tech hardware is giving the fund extra lift, even if past quarters were a bit mixed. On the flip side, SpaceX has been dragging performance, reminding investors that this IPO-focused, U.S.-only fund comes with both exciting upside and some bumpy rides.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 SPCX | SpaceX | 9.24% | $127.34M | $2.02T | -7.69% | ―― |
 LLY | Eli Lilly & Co | 8.28% | $114.16M | $1.21T | 55.12% | 72Outperform |
 GEV | GE Vernova Inc. | 7.36% | $101.49M | $238.39B | 53.16% | 69Neutral |
 SNDK | SanDisk Corp | 5.46% | $75.31M | $188.59B | 639.33% | 55Neutral |
 STX | Seagate Tech | 4.17% | $57.47M | $151.86B | 189.97% | 68Neutral |
 DINO | HF Sinclair Corporation | 3.25% | $44.82M | $20.30B | 108.64% | 68Neutral |
 LITE | Lumentum Holdings | 2.67% | $36.75M | $78.46B | 346.95% | 61Neutral |
 CPAY | Corpay Inc | 2.09% | $28.77M | $26.07B | 39.68% | 75Outperform |
 TWLO | Twilio | 2.01% | $27.74M | $39.09B | 122.34% | 70Neutral |
 GS | Goldman Sachs Group | 1.89% | $26.11M | $265.48B | 15.42% | 73Outperform |
FPX Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For FPX, the sentiment is Negative. The current price of 172.32 is below the 20-day moving average (MA) of 175.89, below the 50-day MA of 178.81, and below the 200-day MA of 178.03, indicating a bearish trend. The MACD of -2.50 indicates Positive momentum. The RSI at 43.27 is Neutral, neither overbought nor oversold. The STOCH value of 27.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FPX.
FPX Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| FPX | $172.32 | $183.00(6.20% Upside) | $1.35B | 0.57% | 54Neutral |
 BBUS | $138.83 | $167.95(20.97% Upside) | $9.60B | 0.02% | 73Outperform |
 DSI | $147.25 | $178.04(20.91% Upside) | $5.48B | 0.25% | 74Outperform |
 QLTY | $43.66 | $52.31(19.81% Upside) | $5.44B | 0.50% | 75Outperform |
 AKRE | $58.26 | $72.24(23.99% Upside) | $4.96B | 0.98% | 68Neutral |
 VTHR | $338.55 | $415.02(22.59% Upside) | $4.86B | 0.06% | 73Outperform |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| FPX | First Trust US Equity Opportunities ETF | 172.32 | 2.44 | 1.43% | |
| BBUS | JP Morgan Betabuilders U.S. Equity ETF | 138.83 | 15.66 | 12.71% | |
| DSI | iShares MSCI KLD 400 Social ETF | 147.25 | 17.74 | 13.70% | |
| QLTY | GMO U.S. Quality ETF | 43.66 | 6.10 | 16.24% | |
| AKRE | Akre Focus ETF | 58.26 | -6.59 | -10.16% | |
| VTHR | Vanguard Russell 3000 ETF | 338.55 | 39.32 | 13.14% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.